Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALPNNASDAQ:GMABNASDAQ:SMMTNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shs2 shsGMABGenmab A/S$22.82-1.2%$20.56$17.24▼$28.56$14.63B0.961.17 million shs1.11 million shsSMMTSummit Therapeutics$19.78-1.9%$23.68$6.78▼$36.91$14.69B-1.063.65 million shs2.89 million shsUTHRUnited Therapeutics$283.35-1.0%$300.50$266.98▼$417.82$12.78B0.57452,793 shs564,424 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%GMABGenmab A/S0.00%+2.79%+16.13%+11.26%-14.76%SMMTSummit Therapeutics0.00%-3.93%-14.34%-4.86%+139.76%UTHRUnited Therapeutics0.00%-13.03%-6.77%-7.78%+0.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune SciencesN/AN/AN/AN/AN/AN/AN/AN/AGMABGenmab A/S3.8235 of 5 stars3.35.00.00.02.40.03.1SMMTSummit Therapeutics3.0602 of 5 stars4.43.00.00.02.61.70.0UTHRUnited Therapeutics4.9913 of 5 stars4.35.00.04.62.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences 0.00N/AN/AN/AGMABGenmab A/S 2.69Moderate Buy$39.1771.63% UpsideSMMTSummit Therapeutics 2.77Moderate Buy$35.0977.41% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$393.0838.72% UpsideCurrent Analyst Ratings BreakdownLatest ALPN, SMMT, UTHR, and GMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/11/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.006/2/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.005/1/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$346.00 ➝ $348.005/1/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$355.00 ➝ $350.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$56.52M78.85N/AN/A$4.85 per share13.40GMABGenmab A/S$3.12B4.70$1.54 per share14.80$8.04 per share2.84SMMTSummit Therapeutics$700K20,985.62N/AN/A$0.11 per share179.82UTHRUnited Therapeutics$2.99B4.27$17.04 per share16.63$127.35 per share2.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/AGMABGenmab A/S$1.14B$1.7613.1112.822.6536.30%16.78%13.79%8/14/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)UTHRUnited Therapeutics$984.80M$25.0612.4410.310.9740.31%19.22%16.15%7/30/2025 (Estimated)Latest ALPN, SMMT, UTHR, and GMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A9.569.56GMABGenmab A/SN/A5.255.24SMMTSummit TherapeuticsN/A8.318.31UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%GMABGenmab A/S7.07%SMMTSummit Therapeutics4.61%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%GMABGenmab A/S1.54%SMMTSummit Therapeutics84.90%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14268.60 million39.58 millionOptionableGMABGenmab A/S1,660641.22 million651.58 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionableUTHRUnited Therapeutics98045.11 million39.33 millionOptionableALPN, SMMT, UTHR, and GMAB HeadlinesRecent News About These Companies328,783 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Vaughan Nelson Investment Management L.P.June 15 at 5:55 AM | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)June 14 at 4:05 AM | marketbeat.comTobam Sells 11,834 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 13 at 6:23 AM | marketbeat.com3,900 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Polianta LtdJune 13 at 5:54 AM | marketbeat.comGreenwood Capital Associates LLC Acquires Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)June 13 at 5:26 AM | marketbeat.comAssenagon Asset Management S.A. Purchases 10,290 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 13 at 4:36 AM | marketbeat.comUnited Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?June 13 at 3:36 AM | zacks.comBank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $315.00June 13 at 1:19 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Cut to $315.00 by Analysts at Bank of AmericaJune 11, 2025 | marketbeat.comUnited Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying StockJune 11, 2025 | seekingalpha.comUnited Therapeutics: Strong Market Position and Growth Potential Amidst Emerging CompetitionJune 11, 2025 | tipranks.comJames Edgemond Sells 12,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJune 10, 2025 | marketbeat.comInsmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial ResultsJune 10, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Down - Here's What HappenedJune 10, 2025 | marketbeat.comAtwood & Palmer Inc. Sells 879 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 10, 2025 | marketbeat.comCantor Fitzgerald Forecasts UTHR FY2026 EarningsJune 10, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by Nepsis Inc.June 10, 2025 | marketbeat.comLiquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH assetJune 10, 2025 | seekingalpha.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Livforsakringsbolaget Skandia OmsesidigtJune 10, 2025 | marketbeat.comToth Financial Advisory Corp Has $404,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)June 10, 2025 | marketbeat.comQ2 EPS Forecast for United Therapeutics Boosted by AnalystJune 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPN, SMMT, UTHR, and GMAB Company DescriptionsAlpine Immune Sciences NASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Genmab A/S NASDAQ:GMAB$22.82 -0.27 (-1.17%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$22.81 -0.01 (-0.04%) As of 06/13/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Summit Therapeutics NASDAQ:SMMT$19.78 -0.38 (-1.88%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$19.76 -0.03 (-0.13%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.United Therapeutics NASDAQ:UTHR$283.35 -2.79 (-0.98%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$282.38 -0.98 (-0.34%) As of 06/13/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
